Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 1
1983 1
1984 1
1985 2
1987 1
1988 1
1989 1
1990 2
1991 2
1995 2
1996 1
1999 1
2000 2
2001 3
2003 1
2005 1
2006 2
2007 1
2008 3
2009 5
2010 3
2011 3
2012 4
2013 3
2014 6
2015 3
2016 4
2017 7
2018 7
2019 4
2020 6
2021 7
2022 8
2023 12
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.
Heymans S, Lakdawala NK, Tschöpe C, Klingel K. Heymans S, et al. Lancet. 2023 Sep 16;402(10406):998-1011. doi: 10.1016/S0140-6736(23)01241-2. Lancet. 2023. PMID: 37716772 Review.
This definition has been recognised as overly restrictive, as left ventricular hypokinesis without dilation could be the initial presentation of dilated cardiomyopathy. The causes of dilated cardiomyopathy comprise genetic (primary dilated cardiomyopathy …
This definition has been recognised as overly restrictive, as left ventricular hypokinesis without dilation could be the initial pres …
2023 ESC Guidelines for the management of cardiomyopathies.
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. Arbelo E, et al. Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194. Eur Heart J. 2023. PMID: 37622657 No abstract available.
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Kittleson MM, et al. Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Circulation. 2020. PMID: 32476490 Free article. Review.
Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Enthus …
Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular depositi …
Cardiac Amyloidosis Treatment.
Stern LK, Patel J. Stern LK, et al. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):59-72. doi: 10.14797/mdcvj.1050. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 35414852 Free PMC article. Review.
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen sign …
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment opt …
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
Siddiqi OK, Ruberg FL. Siddiqi OK, et al. Trends Cardiovasc Med. 2018 Jan;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004. Epub 2017 Jul 13. Trends Cardiovasc Med. 2018. PMID: 28739313 Free PMC article. Review.
Treatment is aimed at relieving congestive symptoms and targeting the underlying amyloidogenic process. This includes anti-plasma cell therapy in AL amyloidosis, and stabilization of the TTR tetramer or inhibition of TTR protein production in ATTR amyloidosis. Cardiac tran …
Treatment is aimed at relieving congestive symptoms and targeting the underlying amyloidogenic process. This includes anti-plasma cell th …
State-of-the-art document on optimal contemporary management of cardiomyopathies.
Seferović PM, Polovina M, Rosano G, Bozkurt B, Metra M, Heymans S, Mullens W, Bauersachs J, Sliwa K, de Boer RA, Farmakis D, Thum T, Olivotto I, Rapezzi C, Linhart A, Corrado D, Tschöpe C, Milinković I, Bayes Genis A, Filippatos G, Keren A, Ašanin M, Krljanac G, Maksimović R, Skouri H, Ben Gal T, Moura B, Volterrani M, Abdelhamid M, Lopatin Y, Chioncel O, Coats AJS. Seferović PM, et al. Eur J Heart Fail. 2023 Nov;25(11):1899-1922. doi: 10.1002/ejhf.2979. Epub 2023 Sep 24. Eur J Heart Fail. 2023. PMID: 37470300 Review.
Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical …
Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-b …
Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association.
Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM, Feingold B, Lal AK, Lee TM, Canter CE, Lipshultz SE; American Heart Association Young Hearts Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts). Bogle C, et al. Circulation. 2023 Jul 11;148(2):174-195. doi: 10.1161/CIR.0000000000001151. Epub 2023 Jun 8. Circulation. 2023. PMID: 37288568 Review.
Other less frequent cardiomyopathies, including left ventricular noncompaction, restrictive cardiomyopathy, and arrhythmogenic cardiomyopathy, are discussed in less detail. ...These differences will likely affect the utility of some adult therapy strat …
Other less frequent cardiomyopathies, including left ventricular noncompaction, restrictive cardiomyopathy, and arrhythmogenic …
Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM; ACMG Professional Practice and Guidelines Committee. Hershberger RE, et al. Genet Med. 2018 Sep;20(9):899-909. doi: 10.1038/s41436-018-0039-z. Epub 2018 Jun 14. Genet Med. 2018. PMID: 29904160 Free article.
PURPOSE: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. ...RESULTS: A genetic evaluation of cardiomyopathy is indicated with …
PURPOSE: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach …
Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria.
Welch TD, Ling LH, Espinosa RE, Anavekar NS, Wiste HJ, Lahr BD, Schaff HV, Oh JK. Welch TD, et al. Circ Cardiovasc Imaging. 2014 May;7(3):526-34. doi: 10.1161/CIRCIMAGING.113.001613. Epub 2014 Mar 14. Circ Cardiovasc Imaging. 2014. PMID: 24633783
BACKGROUND: Constrictive pericarditis is a potentially reversible cause of heart failure that may be difficult to differentiate from restrictive myocardial disease and severe tricuspid regurgitation. Echocardiography provides an important opportunity to evaluate for constr …
BACKGROUND: Constrictive pericarditis is a potentially reversible cause of heart failure that may be difficult to differentiate from rest …
Clinical management of amyloid cardiomyopathy.
Kim MM, Kolseth CM, Carlson D, Masri A. Kim MM, et al. Heart Fail Rev. 2022 Sep;27(5):1549-1557. doi: 10.1007/s10741-021-10159-w. Epub 2021 Sep 1. Heart Fail Rev. 2022. PMID: 34471997 Review.
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical manag …
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In …
101 results